Kamada Reports Discussions with Takeda Regarding a Potential Extension of the Period for the Transition of GLASSIA Manufacturing to Takeda
August 08, 2019 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, reports that it is currently in discussions with Takeda...
Kamada Reports Financial Results for Second Quarter and First Six Months of 2019
August 06, 2019 07:15 ET
|
Kamada Ltd.
Total Revenues for Second Quarter of 2019 were $35.3 Million, a 4% Increase Year-Over-YearTotal Revenues for First Six Months of 2019 were $62.1 Million, a 21% Increase Year-Over-YearGross Profit for...
Kamada to Report Second Quarter 2019 Financial Results and Host Conference Call on August 6
July 31, 2019 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, July 31, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for...
Kamada Reports Financial Results for First Quarter of 2019
May 14, 2019 07:00 ET
|
Kamada Ltd.
Total Revenues for Q1 2019 were $26.8 Million, up 54% over Q1 2018Q1 2019 Proprietary Products Revenues up 67% Year-over-Year Gross Profit for Q1 2019 Grew 59% Year-over-YearAdjusted EBITDA was $6.6...
Kamada to Report First Quarter 2019 Financial Results and Host Conference Call on May 14
May 07, 2019 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, May 07, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the...
Kamada announces FDA acceptance of Inhaled AAT program path forward
April 16, 2019 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, April 16, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq & TASE: KMDA), a plasma-derived protein therapeutics company, today announced receipt of a letter from the U.S. Food and...
Kamada Awarded the Israeli Outstanding Exporter Award for 2017
March 14, 2019 07:00 ET
|
Kamada Ltd.
Company received the award from the Israeli Minister of Economy and Industry for its growing export revenues For fiscal 2017, Kamada's total revenues were $102.8 Million, an increase of more than 33%...
Kamada Files Annual Report for the Year Ended December 31, 2018
February 27, 2019 09:00 ET
|
Kamada Ltd.
REHOVOT, Israel, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it has filed its annual report on Form...
Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2018
February 12, 2019 06:00 ET
|
Kamada Ltd.
Total Revenues for Fiscal 2018 were $114.5 Million, up 11% Over Fiscal 2017; In-line with Recently Provided 2018 Expected Revenues of $113 Million and $115 Million Full-Year Proprietary Products...
Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
February 06, 2019 07:00 ET
|
Kamada Ltd.
Kamada’s IV-AAT demonstrated a trend towards improvements in multiple clinical outcomes, including days on mechanical ventilation post-transplant, pulmonary function at week 4 and week 48...